❤️We are providing a wide range of human tissue solutions based on our Nexocyt platform to build the future of cardiac health. Discover more about our ongoing work to advance drug development and to make caridac repair possible.
👉https://t.co/c6pQlt5VUC
More than 100 years after the discovery of insulin, type 1 diabetes remains a chronic disease that requires lifelong daily management.
A special issue looked at the advances that have expanded researchers’ grasp of this disease. Learn more on #WorldDiabetesDay: https://t.co/SDzTqzY6LR
❤️We are providing a wide range of human tissue solutions based on our Nexocyt platform to build the future of cardiac health. Discover more about our ongoing work to advance drug development and to make caridac repair possible.
👉https://t.co/c6pQlt5VUC
⭐️BIO-Europe is just around the corner and we are excited to explore how we can collaborate to transform the way we treat diseases. Connect with us to learn more about our tissue-based solutions for drug screening and regenerativ medicine.
👉https://t.co/qd8uaLRJmU
#bioeurope
BIRDIE is a marriage between technical innovation and groundbreaking biological science. We spoke to Niek Welkenhuysen at @FluicellAB about the importance of letting the needs of researchers drive technology development.
Read his thoughts here: https://t.co/17iRm9V9w6
Fluicell is developing tissue-based type 1 diabetes therapeutics based on our Nexocyte platform technology. Today, we spoke to our CTO Gavin Jeffries about how development is progressing and what makes Fluicell's therapeutic solutions stand out.
👉https://t.co/5X5oGbL2I8
Meet Aleksandra Rak-Raszewska, postdoctoral scholar and stem cell expert at @MaastrichtU. We spoke to Aleksandra about the value of collaboration in research and how she discovered her passion for science when studying frogs as a child.
👉 https://t.co/bJYqKpvBKt
💡How do cells regulate carbon metabolism?
In a recent study, researchers at @chalmersuniv show that yeast cells control carbon source use by altering the subcellular protein localization in response to changes in their environment.
👇
https://t.co/t9bKAll789
#singlecell
We are excited to announce that we have entered a collaboration with Cellectricon, a leading drug discovery service provider, to validate our Nexocyte tissue models using key research workflows.
Read more about the collaboration 👇
https://t.co/WGwvwRJmng
#bioprinting
🚀Haylie Helms of @OHSUKnight is using Biopixlar to create tumor models with single-cell precision and is presenting her work at the @AACR meeting in San Diego today. We took the opportunity to speak to Haile about her research.
👉https://t.co/TyICX4ALl2
Fluicell’s technologies have played a key role in many discoveries and scientific breakthroughs across multiple different research areas.
Step into our world of discovery and explore Fluicell's publication library: https://t.co/hGID6dmzKN
#bioprinting#research#singlecell
The Biopixlar station at Maastricht University just received an upgrade. With the latest version of the bioprinting platform and a brand new Erlab H-Box biosafety cabinet, we are ready to make new discoveries!
@FluicellAB@MERLN_UM@ErlabSafety#bioprinting
Researchers at @BionomicsLtd have discovered a new compound with potential for treating anxiety- and stress-related disorders. In their study, the researcher used Dynaflow Resolve to perform electrophysiology assays.
Read more 👇
https://t.co/dQvqN1UHMv
Take the opportunity to listen to Fluicell's CEO talk about our many ongoing projects and what our plans are for the future. After the presentation, there will be opportunities to ask questions to Carolina.
Sign up 👉 https://t.co/J2JxbCR5kW…(presentation in 🇸🇪)
We are happy to announce that we have received positive results from the in vivo study that we initiated in December. In the study we evaluated the implant designs and manufacturing processes used in our type 1 diabetes tissue therapeutics program.
👉https://t.co/LwoXFLJUDA
We are pround to be working together with the talented and innovative team at @ConScienceAB to push the boundaries in microfluidic device fabrication and look forward to following their many exciting projects going forward.
2023 was an exciting year for ConScience, we were happy to welcome 30 new clients, and saw increased activity among our established collaborators. Our #Quantum activities were taking off, with support from @vinnovase and the Smart electronics initiative. This lead to the shipment of the first wafer of #quantumcomponents to the US. We also presented our first quantum devices at the European Flagship conference EQTC
https://t.co/QDp8WFUfwB
@QuantumFlagship
In the area of microfluidics, we were happy to launch our first standardised #microfluidics devices together with @FluicellAB .
@AppliedReview listed us a top 10 emerging cleanroom company
https://t.co/Gf8sBwP4Ni
Last but not least, we were happy to welcome senior cleanroom engineer Vladimir Drakinskiy to our team of cleanroom experts.
We can't wait to share what ConScience have in store for 2024.
Best wishes for the new year.
CS team
We are super excited to finaly be able to present our new visual and our tissue therapeutic platform Nexocyte which together solidifies or vision to tranform how we treat disease. Read more on of fresh new home!
👉https://t.co/f6gk0vOHis
Researchers at @ChildrensPhila have created a stem cell-based neuron model to study genetic causes for epilepsy. In their work, they used BioPen together with the model to discover compounds with the ability to restore neuron function.
Read more 👇
https://t.co/k51zyOQfoH